Personalized Medicine Educational Opportunity: Physicians' Knowledge | Diaceutics

Personalized Medicine Educational Opportunity: Physicians’ Knowledge


Stakeholders in personalized medicine are currently missing out on the considerable opportunity to offer physicians information and education on molecular testing. This case study examines how the physicians' education gap might impact on your Rx/Dx launch. It will help you understand:
  • That there are gaps in physicians' knowledge about genomic-based medicine, however, they are willing to learn more
  • What potential sources of information physicians would like to use to learn more about genomic-based medicine
  • That awareness alone does little to prompt usage of molecular tests as most physicians require a thorough understanding to order tests
Download this case study to learn more.

1: Case Summary

This case will help you understand:

That there are gaps in physicians' knowledge about genomic-based medicine, however, they are willing to learn more.

What potential sources of information physicians would like to use to learn more about genomic-based medicine.

That awareness alone does little to prompt usage of molecular tests as most physicians require a thorough understanding to order tests.

Key messages:

Physicians believe genetics and molecular diagnostics have a major influence on their work, however, their knowledge about these subjects is insufficient.

Physicians across therapeutic areas are not sufficiently confident in their ability to order the right molecular tests and interpret them appropriately for their patients.

All stakeholders are currently missing out on a considerable opportunity to offer physicians information and education on molecular testing.

Key actions:

Understand how the physician education gap might impact your Rx/Dx launch.

Plan for physicians' education around testing.

2: CAHG Physician Study

So What?

The study comprised a web-based survey of over 120 questions and was conducted from July to August 2010.

800 US physicians were surveyed: 300 in primary care, 250 in cardiology and 250 in oncology.

The physicians were screened to represent the population in terms of practice setting, location and gender.

A broad range of issues were covered and a rich array of information was collected.

Commentary

Prior to being asked any questions about “genomics-based medicine”, the following definition was provided to physicians:

Please note that we will be using the term “genomics-based medicine” throughout this survey. When we say genomics-based medicine, we mean the following:

Utilization of an individual’s genomic information for: identifying pre-symptomatic risk for developing a disease or condition; screening and diagnosis; disease prognosis and staging; and selection of optimal treatment.  This is also referred to as “Personalized Medicine” and “Molecular Medicine”.

3: Genetics Influence on Patients' Response

Do you believe a patient's genetic profile may influence his/her response to drug therapy?

 

Display_divSlide256_1476js();

 

So What?

The vast majority of physicians across all three surveyed specialties are aware of the impact their patients' genetics have on treatment decisions.

4: Previous Genomics Education

In which of the following settings, if any, have you had education or training in genomics-based medicine?

 

Display_divSlide256_3402js();

So What?

Fewer than one in five physicians (overall) were educated about genomics in medical school, and half say they have received no education or training in genomics-based medicine. 

Both PCPs and oncologists are significantly more likely to say they received education in genomics in medical school compared to cardiologists.

Oncologists are more likely to have received post-medical school training in genomics.

5: Genomics Knowledge and Use

How familiar are you with current issues and advances in genomics-based medicine? 

 

Display_divSlide256_3401js();

So What?

Relatively small numbers across all surveyed specialties, even oncologists, feel “very” familiar with genomics-based medicine.  

Only slightly more than half of PCPs feel “very” or “somewhat” familiar with the field, while 90 per cent of oncologists feel familiar. 

6: Learning about Genomics

How interested are you in learning more about genomics-based medicine as it relates to your practice?

 

Display_divSlide256_3894js();

So What?

A vast majority of all physicians express some level of interest in learning more about genomics-based medicine as it relates to their practice.   

Oncologists are significantly more likely to say they are “very interested” in learning more.  

7: Learning about Genomics: Qualitative Insight

 
 
I am somewhat satisfied but by no means claim that I know everything about the topic. I think most of my knowledge just comes from the fact that I find the subject very interesting.
– Amit, PCP
 
 
I definitely think more needs to be learned and taught, since this is a complex science. But I feel fairly comfortable talking about it with patients when needed.
– Roseleen, Oncologist 

 

Qualitative insight collected via online discussion boards, one each among PCPs, cardiologists, and oncologists. Conducted November, 2009

 

So What?

While some physicians are learning about genomics through intellectual curiosity, others are only learning the “need to know” information relevant to their practice.

8: Major Education Opportunity for All Stakeholders

  • Where do you currently find information about genomics-based medicine?
  • Where would you like to find such information? 
 CurrentDesiredGap
Medical Conferences 51% 88% -37
CME Courses 49% 77% -28
Peer-Reviewed Journals 48% 75% -27
Colleagues/Peers 32% 62% -30
Guidelines 28% 36% -8
Key Opinion Leaders 21% 69% -48
Pharmaceutical Companies 20% 74% -54
Medical Associations 17% 83% -66
FDA/Government Sources 15% 86% -71
University/Academia 15% 56% -41
Molecular Diagnostic Companies 10% 69% -59
Social Networks/Blogs
(e.g, Sermo)
8% 49% -41



 

So What?

Performing a gap analysis between where physicians currently find information about genomics-based medicine, and where they would like to find such information, reveals that physicians feel under-served by pharmaceutical and diagnostics companies when it comes to education and information about novel tests and testing approaches.

9: Meeting with Sales Representatives

  • How interested are you in meeting with a pharmaceutical rep to learn about targeted therapies?
  • How interested are you in meeting with a diagnostics rep to learn about molecular diagnostics?
Display_divSlide256_1479js();

 

So What?

The majority of physicians surveyed expressed an interest in learning more about personalized medicine and engaging with industry reps.

10: Key Messages

Key messages:

Physicians believe genetics and molecular diagnostics have a major influence on their work, however, their knowledge about these subjects is insufficient.

Physicians across therapeutic areas are not sufficiently confident in their ability to order the right molecular tests and interpret them appropriately for their patients.

All stakeholders are currently missing out on a considerable opportunity to offer information and education on molecular testing to physicians.

Key actions:


Understand how the physicians' education gap might impact on your Rx/Dx launch.

Plan for physicians' education around testing.

Expert Insights

View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
View all publications
Facebook
Twitter
YouTube
LinkedIn